CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
病例报告：帕纳替尼作为复发/难治性费城染色体样急性淋巴细胞白血病患者的 CAR-T 细胞桥接及后续维持治疗
英文原题：Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia.
查看英文原题
Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
Ph样急性淋巴细胞白血病（ALL）是一种异质性ALL亚群，预后普遍不良。鉴定可用酪氨酸激酶抑制剂（TKI）治疗的突变，是一个有前景的研究方向。本文报告一例年轻复发/难治性Ph样ALL患者病例；该患者接受CAR-T（CAR-T）细胞治疗前，以同情用药方式使用ponatinib和低剂量泼尼松龙成功桥接。3个月后重新开始低剂量ponatinib维持治疗。20个月后，患者仍为可测量残留病阴性并维持B细胞再生障碍。据我们所知，这是首例报告ponatinib用于Ph样ALL患者CAR-T 治疗前桥接及治疗后维持的病例。
展开英文摘要原文
Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) constitutes a heterogeneous subset of ALL with a uniformly unfavorable prognosis. The identification of mutations amenable to treatment with tyrosine kinase-inhibitors (TKIs) represents a promising field of investigation.
We report the case of a young patient affected by relapsed/refractory Ph-like ALL treated with chimeric antigen receptor T (CAR-T) cells after successful bridging with compassionate-use ponatinib and low-dose prednisone.
We restarted low-dose ponatinib maintenance three months later. Twenty months later, measurable residual disease negativity and B-cell aplasia persist. To the best of our knowledge, this is the first case reporting the use of ponatinib in Ph-like ALL as a bridge to and maintenance after CAR-T cell therapy.
论文信息
- 作者
- Giglio F、Campodonico E、Lorentino F、Noviello M、Xue E、Greco R、Lazzari L、Bruno A
- 单位
- Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.Italy
- 文献类型
- 病例报告
- 期刊
- Frontiers in oncology2022
- 原文标识
- PubMed 36733349 · DOI 10.3389/fonc.2022.1100105
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →